Genzyme's ( GENZ) third-quarter earnings rose 18% from a year ago and beat analysts' forecasts thanks to fattening margins.

The Massachusetts-based biotech earned $115.7 million, or 43 cents a share, in the quarter, compared with $97.8 million, or 41 cents a share, a year ago. Excluding items including amortization, Genzyme's earnings rose 38% to $160.5 million, or 61 cents a share, beating the Thomson First Call consensus by a nickel.

The stock added about 1% to $70.02 early Tuesday.

Revenue rose 24% from a year ago to $708.1 million, about $8 million ahead of forecasts. Sales of Genzyme's biggest drug, Cerezyme for Gaucher disease, rose 14% from a year ago to $238.3 million, while sales of Renagel, a drug for kidney disease, rose 15% from a year ago to $106.9 million in the latest quarter.

Sales of the knee-pain treatment Synvisc more than doubled to $57.7 million after the company acquired sales rights for the drug in the U.S. and five European countries. That performance helped boost Genzyme's overall third-quarter gross margin to 78% from 73%.

Sales of the Fabry disease treatment Fabrazyme rose 36% to $79.1 million, while sales of enzyme replacement Aldurazyme doubled to $20.1 million.

More from Stocks

Palo Alto Networks Is Set for an Upside Breakout and Rally Back to the Highs

Palo Alto Networks Is Set for an Upside Breakout and Rally Back to the Highs

Dow Soars on Signs of Progress in U.S.-China Trade Discussions

Dow Soars on Signs of Progress in U.S.-China Trade Discussions

Under Armour Is Tripped Up by Concerns Over North American Sales

Under Armour Is Tripped Up by Concerns Over North American Sales

FedEx and UPS Set to Deliver Gains During Santa Claus Rally

FedEx and UPS Set to Deliver Gains During Santa Claus Rally

Chart of the Day: Can Dave & Buster's Benefit From the Fall of the Mall?

Chart of the Day: Can Dave & Buster's Benefit From the Fall of the Mall?